Difference between revisions of "Liposarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8}) Clinical Trial Registry" to "$1 $1") |
||
| Line 89: | Line 89: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''ET743-SAR-3007:''' Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. [https://doi.org/10.1200/jco.2015.62.4734 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26371143/ PubMed] [https://clinicaltrials.gov/study/NCT01343277 | + | # '''ET743-SAR-3007:''' Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. [https://doi.org/10.1200/jco.2015.62.4734 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26371143/ PubMed] [https://clinicaltrials.gov/study/NCT01343277 NCT01343277] |
## '''Subgroup analysis:''' Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. [https://doi.org/10.1016/j.ygyno.2017.06.018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5783302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28651804/ PubMed] | ## '''Subgroup analysis:''' Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. [https://doi.org/10.1016/j.ygyno.2017.06.018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5783302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28651804/ PubMed] | ||
## '''Update:''' Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. [https://doi.org/10.1002/cncr.32117 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31173362/ PubMed] | ## '''Update:''' Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. [https://doi.org/10.1002/cncr.32117 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31173362/ PubMed] | ||
| − | # '''E7389-G000-309:''' Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. [https://doi.org/10.1016/S0140-6736(15)01283-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26874885/ PubMed] [https://clinicaltrials.gov/study/NCT01327885 | + | # '''E7389-G000-309:''' Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. [https://doi.org/10.1016/S0140-6736(15)01283-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26874885/ PubMed] [https://clinicaltrials.gov/study/NCT01327885 NCT01327885] |
## '''Subgroup analysis:''' Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017 Oct 20;35(30):3433-3439. Epub 2017 Aug 30. [https://doi.org/10.1200/JCO.2016.71.6605 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28854066/ PubMed] | ## '''Subgroup analysis:''' Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017 Oct 20;35(30):3433-3439. Epub 2017 Aug 30. [https://doi.org/10.1200/JCO.2016.71.6605 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28854066/ PubMed] | ||
==Eribulin monotherapy {{#subobject:427859|Regimen=1}}== | ==Eribulin monotherapy {{#subobject:427859|Regimen=1}}== | ||
| Line 126: | Line 126: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''E7389-G000-309:''' Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. [https://doi.org/10.1016/S0140-6736(15)01283-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/26874885/ PubMed] [https://clinicaltrials.gov/study/NCT01327885 | + | # '''E7389-G000-309:''' Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. [https://doi.org/10.1016/S0140-6736(15)01283-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/26874885/ PubMed] [https://clinicaltrials.gov/study/NCT01327885 NCT01327885] |
## '''Subgroup analysis:''' Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017 Oct 20;35(30):3433-3439. Epub 2017 Aug 30. [https://doi.org/10.1200/JCO.2016.71.6605 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28854066/ PubMed] | ## '''Subgroup analysis:''' Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017 Oct 20;35(30):3433-3439. Epub 2017 Aug 30. [https://doi.org/10.1200/JCO.2016.71.6605 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28854066/ PubMed] | ||
==Trabectedin monotherapy {{#subobject:cfc3ed|Regimen=1}}== | ==Trabectedin monotherapy {{#subobject:cfc3ed|Regimen=1}}== | ||
| Line 165: | Line 165: | ||
===References=== | ===References=== | ||
# Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188-96. Epub 2009 Aug 3. [https://doi.org/10.1200/JCO.2008.21.0088 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/19652065/ PubMed] | # Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188-96. Epub 2009 Aug 3. [https://doi.org/10.1200/JCO.2008.21.0088 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/19652065/ PubMed] | ||
| − | # '''ET743-SAR-3007:''' Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. [https://doi.org/10.1200/jco.2015.62.4734 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26371143/ PubMed] [https://clinicaltrials.gov/study/NCT01343277 | + | # '''ET743-SAR-3007:''' Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. [https://doi.org/10.1200/jco.2015.62.4734 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26371143/ PubMed] [https://clinicaltrials.gov/study/NCT01343277 NCT01343277] |
## '''Subgroup analysis:''' Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. [https://doi.org/10.1016/j.ygyno.2017.06.018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5783302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28651804/ PubMed] | ## '''Subgroup analysis:''' Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. [https://doi.org/10.1016/j.ygyno.2017.06.018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5783302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28651804/ PubMed] | ||
## '''Update:''' Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. [https://doi.org/10.1002/cncr.32117 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31173362/ PubMed] | ## '''Update:''' Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. [https://doi.org/10.1002/cncr.32117 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31173362/ PubMed] | ||
Revision as of 11:21, 4 July 2023
Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
3 regimens on this page
5 variants on this page
|
All lines of therapy
Dacarbazine monotherapy
Regimen variant #1, 850 mg/m2
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Schöffski et al. 2016 (E7389-G000-309) | 2011-2013 | Phase 3 (C) | Eribulin | Inferior OS1 |
1Reported efficacy is based on the 2017 subgroup analysis.
Regimen variant #2, 1000 mg/m2
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Demetri et al. 2015 (ET743-SAR-3007) | 2011-2013 | Phase 3 (C) | Trabectedin | Did not meet primary endpoint of OS |
| Schöffski et al. 2016 (E7389-G000-309) | 2011-2013 | Phase 3 (C) | Eribulin | Inferior OS1 |
1Reported efficacy is based on the 2017 subgroup analysis.
Note: this is listed as a "starting dose" in Demetri et al. 2015, but no adjustment instructions were provided in the manuscript.
Regimen variant #3, 1200 mg/m2
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Schöffski et al. 2016 (E7389-G000-309) | 2011-2013 | Phase 3 (C) | Eribulin | Inferior OS1 |
1Reported efficacy is based on the 2017 subgroup analysis.
Chemotherapy
- Dacarbazine (DTIC) 1200 mg/m2 IV over 20 minutes once on day 1
Supportive therapy
- Buesa et al. 1991: Calcium gluconate (10% solution) 5 mL IV every 10 minutes x 3 doses (total of 15 mL) after the start of dacarbazine; 2 additional doses of calcium gluconate (10% solution) 5 mL IV every 10 minutes were given to patients whose systolic blood pressure decreased below 80 mmHg or heart rate more than 160 bpm.
21-day cycles
References
- ET743-SAR-3007: Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01343277
- Subgroup analysis: Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. link to original article link to PMC article PubMed
- Update: Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. link to original article link to PMC article PubMed
- E7389-G000-309: Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. link to original article PubMed NCT01327885
- Subgroup analysis: Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017 Oct 20;35(30):3433-3439. Epub 2017 Aug 30. link to original article contains dosing details in manuscript PubMed
Eribulin monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | |
|---|---|---|---|---|---|
Schöffski et al. 2016 (E7389-G000-309)
|
2011-2013 | Phase 3 (E-RT-switch-ic) | Dacarbazine | Superior OS1 Median OS: 15.6 vs 8.4 mo (HR 0.51, 95% CI 0.35-0.75) |
1Reported efficacy is based on the 2017 subgroup analysis.
References
- E7389-G000-309: Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. link to original article contains dosing details in abstract PubMed NCT01327885
- Subgroup analysis: Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017 Oct 20;35(30):3433-3439. Epub 2017 Aug 30. link to original article contains dosing details in manuscript PubMed
Trabectedin monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy | |
|---|---|---|---|---|---|
| Demetri et al. 2009 | 2003-NR | Randomized Phase 2 (E-switch-ic) | Trabectedin; alternate schedule | Seems to have superior TTP | |
Demetri et al. 2015 (ET743-SAR-3007)
|
2011-2013 | Phase 3 (E-RT-switch-ic) | Dacarbazine | Did not meet primary endpoint of OS |
Note: in Demetri et al. 2015, this is listed as a "starting dose," but no adjustment instructions were provided in the manuscript.
Chemotherapy
- Trabectedin (Yondelis) 1.5 mg/m2 IV continuous infusion over 24 hours, started on day 1
Supportive therapy
- Dexamethasone (Decadron) 20 mg IV once on day 1, prior to trabectedin
21-day cycles
References
- Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188-96. Epub 2009 Aug 3. link to original article contains dosing details in abstract PubMed
- ET743-SAR-3007: Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01343277
- Subgroup analysis: Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. link to original article link to PMC article PubMed
- Update: Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. link to original article link to PMC article PubMed